120 related articles for article (PubMed ID: 38284256)
1. [The proportion of CD19
Xie Z; Dai L; He H; Hong D; Wang Y; Xu W; Chen Z; Li B; Xie C
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2024 Feb; 40(2):148-157. PubMed ID: 38284256
[TBL] [Abstract][Full Text] [Related]
2. The blockade of PD-1/PD-L1 pathway promotes the apoptosis of CD19
Wang Z; Tan F
Scand J Immunol; 2020 Feb; 91(2):e12836. PubMed ID: 31598989
[TBL] [Abstract][Full Text] [Related]
3. The role and clinical significance of programmed cell death- ligand 1 expressed on CD19
Jia XY; Zhu QQ; Wang YY; Lu Y; Li ZJ; Li BQ; Tang J; Wang HT; Song CW; Xie CH; Chen LJ
Clin Immunol; 2019 Jan; 198():89-99. PubMed ID: 30502542
[TBL] [Abstract][Full Text] [Related]
4. The effect of PD-1/PD-L1 signaling axis on the interaction between CD19
Xie Z; Dai L; He H; Hong D; Tang H; Xu W; Chen Z; Wang H; Li B; Xie C; Wang Y
Adv Rheumatol; 2023 Oct; 63(1):51. PubMed ID: 37848996
[TBL] [Abstract][Full Text] [Related]
5. PD-L1
Zacca ER; Onofrio LI; Acosta CDV; Ferrero PV; Alonso SM; Ramello MC; Mussano E; Onetti L; Cadile II; Stancich MI; Taboada Bonfanti MC; Montes CL; Acosta Rodríguez EV; Gruppi A
Front Immunol; 2018; 9():2241. PubMed ID: 30327652
[No Abstract] [Full Text] [Related]
6. Patients with systemic lupus erythematosus show increased proportions of CD19
Zhu Q; Li Y; Zhang L; Wang M; Chen Z; Shi J; Li J; Li B; Li Z; Wang Y; Xie C
Clin Rheumatol; 2021 Jan; 40(1):151-165. PubMed ID: 32542581
[TBL] [Abstract][Full Text] [Related]
7. Low expressions of PD-L1 and CTLA-4 by induced CD4
Zhao L; Zhou X; Zhou X; Wang H; Gu L; Ke Y; Zhang M; Ji X; Yang X
Cytokine; 2020 Sep; 133():155119. PubMed ID: 32535334
[TBL] [Abstract][Full Text] [Related]
8. [Analysis of frequency of peripheral blood CD4+; CD25(high);Tregs and CD4+; CD25(low);T cells and expression of PD-1 in SLE and RA patients].
Niu Q; Huang ZC; Cai B; Wang LL; Feng WH
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2011 Jan; 27(1):23-5. PubMed ID: 21208558
[TBL] [Abstract][Full Text] [Related]
9. Expression of CD19+CD24highCD38high B cells, IL‑10 and IL‑10R in peripheral blood from patients with systemic lupus erythematosus.
Wang T; Li Z; Li X; Chen L; Zhao H; Jiang C; Song L
Mol Med Rep; 2017 Nov; 16(5):6326-6333. PubMed ID: 28901380
[TBL] [Abstract][Full Text] [Related]
10. PD-L1 is a critical mediator of regulatory B cells and T cells in invasive breast cancer.
Guan H; Wan Y; Lan J; Wang Q; Wang Z; Li Y; Zheng J; Zhang X; Wang Z; Shen Y; Xie F
Sci Rep; 2016 Oct; 6():35651. PubMed ID: 27762298
[TBL] [Abstract][Full Text] [Related]
11. CD4+CD25+CD127-Foxp3+ and CD8+CD28- Tregs in Renal Transplant Recipients: Phenotypic Patterns, Association With Immunosuppressive Drugs, and Interaction With Effector CD8+ T Cells and CD19+IL-10+ Bregs.
Aly MG; Ibrahim EH; Karakizlis H; Weimer R; Opelz G; Morath C; Zeier M; Ekpoom N; Daniel V
Front Immunol; 2021; 12():716559. PubMed ID: 34335631
[TBL] [Abstract][Full Text] [Related]
12. The interaction between the soluble programmed death ligand-1 (sPD-L1) and PD-1
Li X; Du H; Zhan S; Liu W; Wang Z; Lan J; PuYang L; Wan Y; Qu Q; Wang S; Yang Y; Wang Q; Xie F
Front Immunol; 2022; 13():830606. PubMed ID: 35935985
[TBL] [Abstract][Full Text] [Related]
13. Expression of PD-L1 on regulatory B cells in patients with acute myeloid leukaemia and its effect on prognosis.
Shi Y; Liu Z; Wang H
J Cell Mol Med; 2022 Jun; 26(12):3506-3512. PubMed ID: 35610758
[TBL] [Abstract][Full Text] [Related]
14. CD19(+)IL-10(+) regulatory B cells affect survival of tongue squamous cell carcinoma patients and induce resting CD4(+) T cells to CD4(+)Foxp3(+) regulatory T cells.
Zhou X; Su YX; Lao XM; Liang YJ; Liao GQ
Oral Oncol; 2016 Feb; 53():27-35. PubMed ID: 26631955
[TBL] [Abstract][Full Text] [Related]
15. Restoration of regulatory B cell deficiency following alemtuzumab therapy in patients with relapsing multiple sclerosis.
Kim Y; Kim G; Shin HJ; Hyun JW; Kim SH; Lee E; Kim HJ
J Neuroinflammation; 2018 Oct; 15(1):300. PubMed ID: 30373595
[TBL] [Abstract][Full Text] [Related]
16. [Expression of regulatory B cells in peripheral blood of patients with systemic lupus erythematosus].
Cai X; Li X; Lin X; Tang C; Ye J; Li W; He Z; Li F; Xu Y
Zhonghua Yi Xue Za Zhi; 2015 May; 95(17):1310-3. PubMed ID: 26081660
[TBL] [Abstract][Full Text] [Related]
17. Variable increased expression of program death-1 and program death-1 ligands on peripheral mononuclear cells is not impaired in patients with systemic lupus erythematosus.
Liu MF; Weng CT; Weng MY
J Biomed Biotechnol; 2009; 2009():406136. PubMed ID: 19759858
[TBL] [Abstract][Full Text] [Related]
18. Impaired granzyme B-producing regulatory B cells in systemic lupus erythematosus.
Bai M; Xu L; Zhu H; Xue J; Liu T; Sun F; Yao H; Zhao Z; Wang Z; Yao R; Hu F; Su Y
Mol Immunol; 2021 Dec; 140():217-224. PubMed ID: 34749262
[TBL] [Abstract][Full Text] [Related]
19. Aberrant expression of regulatory cytokine IL-35 in patients with systemic lupus erythematosus.
Cai Z; Wong CK; Kam NW; Dong J; Jiao D; Chu M; Lam CW; Tam LS
Lupus; 2015 Oct; 24(12):1257-66. PubMed ID: 25966926
[TBL] [Abstract][Full Text] [Related]
20. Enhanced Programmed Death 1 and Diminished Programmed Death Ligand 1 Up-Regulation Capacity of Post-Activated Lupus B Cells.
Stefanski AL; Wiedemann A; Reiter K; Hiepe F; Lino AC; Dörner T
Arthritis Rheumatol; 2019 Sep; 71(9):1539-1544. PubMed ID: 30919595
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
